Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 0.75 |
| ▸ | ERBB2 | P04626 | 4/20 | 0.70 |
| ▸ | CIT | O14578 | 1/20 | 0.70 |
| ▸ | GAK | O14976 | 1/20 | 0.70 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.70 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.70 |
| ▸ | STK10 | O94804 | 1/20 | 0.70 |
| ▸ | ABL1 | P00519 | 1/20 | 0.70 |
| ▸ | LCK | P06239 | 1/20 | 0.70 |
| ▸ | LYN | P07948 | 1/20 | 0.70 |
| ▸ | RET | P07949 | 1/20 | 0.70 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.70 |
| ▸ | MET | P08581 | 1/20 | 0.70 |
| ▸ | HCK | P08631 | 1/20 | 0.70 |
| ▸ | SRC | P12931 | 1/20 | 0.70 |
| ▸ | PHKG2 | P15735 | 1/20 | 0.70 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.70 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.70 |
| ▸ | AXL | P30530 | 1/20 | 0.70 |
| ▸ | CCKAR | P32238 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4060171 | 1.00 | EGFR (0.75) | EGFRERBB2CITGAKEPHB6 | |
| SCHEMBL29043124 | 0.91 | EGFR (0.73) | EGFRERBB2CITGAKEPHB6 | |
| SCHEMBL2072074 | 0.91 | EGFR (0.75) | EGFRERBB2CITGAKEPHB6 | |
| SCHEMBL29779503 | 0.91 | EGFR (0.75) | EGFRERBB2CITGAKEPHB6 | |
| SCHEMBL436189 | 0.91 | EGFR (0.75) | EGFRERBB2CITGAKEPHB6 | |
| SCHEMBL436188 | 0.91 | EGFR (0.75) | EGFRERBB2CITGAKEPHB6 | |
| SCHEMBL29838794 | 0.91 | EGFR (0.75) | EGFRERBB2CITGAKEPHB6 | |
| SCHEMBL28415394 | 0.88 | EGFR (0.82) | EGFRERBB2CITGAKEPHB6 | |
| SCHEMBL28415396 | 0.88 | EGFR (0.82) | EGFRERBB2CITGAKEPHB6 | |
| SCHEMBL1364362 | 0.87 | EGFR (0.72) | EGFRERBB2CITGAKEPHB6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3567038-B1 | PROCESS FOR THE PREPARATION OF QUINAZOLINYL DERIVATIVES | HETERO LABS LTD (IN) | 2022-08-10 | — | — | EP | disclosed |
| EP-3567038-A1 | PROCESS FOR THE PREPARATION OF QUINAZOLINYL DERIVATIVES | Hetero Labs Ltd. (IN) | 2019-11-13 | — | — | EP | disclosed |
| US-10329281-B2 | Polymorphs and process for the preparation of quinazolinyl derivatives | HETERO LABS LTD (IN) | 2019-06-25 | — | — | US | disclosed |
| US-20180194754-A1 | Polymorphs and Process for the Preparation of Quinazolinyl Derivatives | HETERO LABS LTD (IN) | 2018-07-12 | — | — | US | disclosed |
| EP-3283485-A2 | POLYMORPHS OF AFATINIB AND ITS SALTS AND PROCESS FOR THE PREPARATION OF QUINAZOLINYL DERIVATIVES | Hetero Labs Ltd. (IN) | 2018-02-21 | — | — | EP | disclosed |
| EP-3089976-A1 | CRYSTALLINE FORMS OF AFATINIB DI-MALEATE | Teva Pharmaceuticals International GmbH (CH) | 2016-11-09 | — | — | EP | disclosed |
| WO-2016166720-A2 | POLYMORPHS AND PROCESS FOR THE PREPARATION OF QUINAZOLINYL DERIVATIVES | HETERO RESEARCH FOUNDATION (IN) | 2016-10-20 | — | — | WO | disclosed |
| US-20150232457-A1 | CRYSTALLINE FORMS OF AFATINIB DI-MALEATE | RATIOPHARM GMBH (DE) | 2015-08-20 | — | — | US | disclosed |
| WO-2015103456-A1 | CRYSTALLINE FORMS OF AFATINIB DI-MALEATE | TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) | 2015-07-09 | — | — | WO | disclosed |
| US-8426586-B2 | Using a acyl bromine compound; activation with phosphonacetic acid | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-04-23 | — | — | US | disclosed |
| US-20070027170-A1 | Process for preparing amino crotonyl compounds | SOYKA RAINER | 2007-02-01 | — | — | US | disclosed |
| US-20050085495-A1 | Process for preparing amino crotonyl compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027170-A1 | Process for preparing amino crotonyl compounds | CROCC, CMA1, IL4I1 | EGFR 3654/4885ERBB2 3381/4885CIT 2532/4885 |
| US-20180194754-A1 | Polymorphs and Process for the Preparation of Quinazolinyl Derivatives | CYP3A4, CYP3A43, CYP2C19 | EGFR 4596/4885ERBB2 4252/4885CIT 2050/4885 |
| US-10329281-B2 | Polymorphs and process for the preparation of quinazolinyl derivatives | CYP3A4, CYP3A43, CYP2C19 | EGFR 4596/4885ERBB2 4252/4885CIT 2050/4885 |
| US-20150232457-A1 | CRYSTALLINE FORMS OF AFATINIB DI-MALEATE | CDC73, ABL1, MLLT3 | EGFR 110/4885ERBB2 84/4885CIT 109/4885 |
| US-20050085495-A1 | Process for preparing amino crotonyl compounds | INMT, IL4I1, HNMT | EGFR 4428/4885ERBB2 3922/4885CIT 244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.